Li Lin, Zhao Qian, Chen Zhiqing, Zhao Zican, Du Baojie, Wang Mixue, Bai Peirong, Wang Xiaozhe, Ren Xiaofeng, Li Liping, Zhang Ruiping
Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, China.
Academy of Medical Sciences, Shanxi Medical University, Taiyuan, 030001, China.
Adv Healthc Mater. 2025 Jan;14(3):e2402307. doi: 10.1002/adhm.202402307. Epub 2024 Nov 18.
Boron neutron capture therapy (BNCT) stands out as a noninvasive potential modality for invasive malignant tumors, with boron drugs playing a crucial role in its efficacy. Nevertheless, the development of boron drugs with biodegradability, as well as high permeability and retention effects, continues to present significant challenges. Here, we fabricate a size-tunable boron nanoreactor (TBNR) via assembling boron nitride quantum dots (BNQDs) and Fe3+ for tumor BNCT and chemodynamic (CDT) synergistic treatment. The obtained TBNR with an appropriate size exhibits superior tumor accumulation and retention. Upon stimulation by the tumor microenvironment (TME), the contained Fe3+ undergo redox reactions with glutathione (GSH) to produce Fe2+ Fenton reagents, which in turn activate CDT function and simultaneously induce TBNR depolymerization. Subsequently, the released ultrasmall BNQDs exhibit intra-deep penetration characteristic and are fully enriched at the tumor site. The in vivo experiments reveal that TBNR possesses excellent biocompatibility and superior synergistic anti-tumor ability post neutron irradiation, resulting in significant shrinkage of subcutaneous 4T1 tumors. Moreover, the TBNR-mediated BNCT has triggered an obvious immune response, which contributes to the long-term suppression of tumors after neutron irradiation. To conclude, this study provides a new approach for constructing more efficient versatile nanocarriers for BNCT-induced combination cancer therapies.
硼中子俘获疗法(BNCT)作为一种针对侵袭性恶性肿瘤的非侵入性潜在治疗方式脱颖而出,硼药物在其疗效中起着关键作用。然而,开发具有生物可降解性以及高渗透性和滞留效应的硼药物仍然面临重大挑战。在此,我们通过组装氮化硼量子点(BNQDs)和Fe3+制备了一种尺寸可调的硼纳米反应器(TBNR),用于肿瘤的BNCT和化学动力学(CDT)协同治疗。所获得的具有合适尺寸的TBNR表现出优异的肿瘤积累和滞留能力。在肿瘤微环境(TME)的刺激下,所含的Fe3+与谷胱甘肽(GSH)发生氧化还原反应生成Fe2+芬顿试剂,进而激活CDT功能并同时诱导TBNR解聚。随后,释放出的超小BNQDs表现出深入渗透的特性,并在肿瘤部位充分富集。体内实验表明,TBNR具有优异的生物相容性,在中子辐照后具有卓越的协同抗肿瘤能力,导致皮下4T1肿瘤显著缩小。此外,TBNR介导的BNCT引发了明显的免疫反应,这有助于中子辐照后对肿瘤的长期抑制。总之,本研究为构建用于BNCT诱导的联合癌症治疗的更高效通用纳米载体提供了一种新方法。